SCHEMBL1574485

SCHEMBL1574485

CCCN(c1ccccc1)C1CN(C(=O)Nc2cccc(F)c2)C1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.51
PAX8 Q06710 3/20 0.46
LMNA P02545 1/20 0.46
ALDH1A1 P00352 5/20 0.46
CYP2D6 P10635 3/20 0.46
UBE2M P61081 2/20 0.46
DCUN1D1 Q96GG9 2/20 0.46
FAAH O00519 2/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
USP2 O75604 3/20 0.44
CYP2C9 P11712 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
CYP3A4 P08684 1/20 0.44
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
ALOX15 P16050 1/20 0.43
HIF1A Q16665 1/20 0.43
EPHX2 P34913 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575761 0.91 UBE2M (0.43) NPC1UBE2MDCUN1D1FAAHSMN1; SMN2
SCHEMBL1575347 0.91 NPC1 (0.53) NPC1PAX8LMNAALDH1A1CYP2D6
SCHEMBL1575336 0.89 HPGD (0.47) NPC1ALDH1A1FAAHCYP2C19CYP2C9
SCHEMBL1574882 0.88 GRIN2B (0.53) ALDH1A1UBE2MDCUN1D1FAAHSMN1; SMN2
SCHEMBL1574710 0.88 GRIN2B (0.52) NPC1PAX8LMNAALDH1A1FAAH
SCHEMBL1575548 0.88 GRIN2B (0.58) LMNAALDH1A1UBE2MDCUN1D1FAAH
SCHEMBL1574757 0.87 GRIN2B (0.54) NPC1LMNAALDH1A1UBE2MDCUN1D1
SCHEMBL1575364 0.85 CYP2D6 (0.50) NPC1PAX8LMNAALDH1A1CYP2D6
SCHEMBL1575185 0.85 S1PR2 (0.51) ALDH1A1FAAHPOLBALOX15EPHX2
SCHEMBL1574553 0.85 MAPT (0.52) LMNAALDH1A1CYP2D6UBE2MDCUN1D1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-B1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO (JP) 2015-02-25 EP disclosed
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB NPC1 413/4885PAX8 2494/4885LMNA 1076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.